Is Zevra Therapeutics Inc. (ZVRA) overvalued? · P/E 6.3, rev $75.9M
Zevra Therapeutics Inc. (ZVRA) is a biotechnology company listed on NASDAQ.
This page asks whether Zevra Therapeutics Inc. (ZVRA) looks expensive on cached numbers — not a short thesis.
Latest reported ZVRA revenue for 2026-06-30 was $75.9M. Net income was $46.6M. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
ZVRA currently screens at market cap $745.4M and trailing P/E 6.3. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ZVRA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ZVRA stock page for the full model, not this heading.
Not investment advice.